Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 27;18(1):126.
doi: 10.1186/s12883-018-1125-1.

Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients

Anca Moţăţăianu  1 , Smaranda Maier  2 , Zoltan Bajko  2 , Septimiu Voidazan  3 , Rodica Bălaşa  2 , Adina Stoian  4
Affiliations

Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients

Anca Moţăţăianu et al. BMC Neurol. .

Abstract

Background: Cardiac autonomic neuropathy (CAN) in diabetes is among the strongest risk markers for future global and cardiovascular mortality. The aim of this study was to analyse CAN prevalence and to compare the associations between CAN, the glycaemic control, cardiovascular risk factors, peripheral neuropathy, retinopathy and macroangiopathy in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM).

Methods: One hundred ninety-five diabetic patients were included in this study. All patients were evaluated for detection of CAN (with standardised cardiovascular reflex tests), diabetes-related microvascular complications (polyneuropathy, retinopathy), common carotid artery intima-media thickness (IMT) and ankle-brachial index (ABI).

Results: The prevalence of CAN was 39.1% in T2DM and 61.8% in T1DM patients. Multivariate logistic regression analysis demonstrated that in T2DM, the odds [OR (95% confidence intervals)] of CAN increased with diabetes duration [1.67(1.42-1.92)], HbA1c [1.74(1.34-2.27)], cholesterol [1.01(1.00-1.01)], triglycerides [1.01(0.99-1.00)], smoking [2.35(1.23-4.49)], systolic blood pressure [1.01(1.00-1.03)], BMI [1.16(1.08-1.24)], glomerular filtration rate [0.91(0.88-0.93)], peripheral neuropathy [25.94(11.04-44.25)], retinopathy [13.13(3.03-84.73)] and IMT [10.12 (7.21-15.32)]. In T1DM, the odds of CAN increased with diabetes duration [1.62(1.13-2.31)], HbA1c [4.49(1.27-15.9)], age of patients [1.14(1.03-1.27)], glomerular filtration rate [0.94(0.89-0.99)], peripheral neuropathy [31.6(4.5-45.8)] and IMT [5.5(2.3-8.3)].

Conclusion: This study indicated that CAN is a more frequent complication in T1DM. Apart from glycaemic control, the existence of CAN is associated with potentially modifiable cardiovascular risk only in T2DM patients. The presence of other micro- and macrovascular complications increases the probability of having CAN in both types of DM (but more pronounced in T2DM).

Keywords: Cardiac autonomic neuropathy; Cardiovascular risk factors; Glycaemic control; Macrovascular complication; Microvascular complication; Type 1 diabetes; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Competing interest

The authors declare that they have no competing interests.

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Mures County Clinical Emergency Hospital (20/01.06.2012). The study participants agreed to participate in this study, and all of them provided written informed consent.

Consent for publication

A written consent form was obtained from all participants for potentially publishing their clinical data while protecting their personal information.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. doi: 10.1016/j.diabres.2017.03.024. - DOI - PubMed
    1. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4–18. doi: 10.1111/jdi.12042. - DOI - PMC - PubMed
    1. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–1579. doi: 10.2337/diacare.26.5.1553. - DOI - PubMed
    1. What PBR. Do we know and what we do not know about cardiovascular autonomic neuropathy in diabetes. J of Cardiovasc Trans Res. 2012;5:463–478. doi: 10.1007/s12265-012-9367-6. - DOI - PMC - PubMed
    1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO) Kidney Int. 2005;67:2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x. - DOI - PubMed